Compare SONO & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | MLTX |
|---|---|---|
| Founded | 2002 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2018 | 2020 |
| Metric | SONO | MLTX |
|---|---|---|
| Price | $15.77 | $17.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $19.67 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,443,276,000.00 | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.12 | $5.95 |
| 52 Week High | $19.82 | $62.75 |
| Indicator | SONO | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 40.28 |
| Support Level | $12.77 | $17.00 |
| Resistance Level | $17.50 | $19.24 |
| Average True Range (ATR) | 1.01 | 0.97 |
| MACD | 0.07 | -0.21 |
| Stochastic Oscillator | 47.72 | 0.71 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.